Skip to main content

Advertisement

SpringerLink
Log in

Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724)

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

A Correction to this article was published on 04 September 2021

This article has been updated

Abstract

Purpose

The current project was developed to obtain natural history information regarding cisplatin-induced peripheral neuropathy in males with testicular/germ cell cancers and to compare such neuropathy data with similarly obtained data in patients receiving other chemotherapy drugs in similarly conducted clinical trials.

Methods

Patients without baseline neuropathy symptoms, who were initiating cisplatin-based chemotherapy, completed the EORTC CIPN 20 patient-reported instrument to evaluate chemotherapy-induced peripheral neuropathy (CIPN). Results were compared with EORTC CIPN 20 data obtained from independent study sets regarding patients receiving (1) paclitaxel, (2) combined paclitaxel and carboplatin, (3) oxaliplatin, or (4) a combination of doxorubicin and cyclophosphamide (AC). The last study set of patients on AC was selected to evaluate the use of EORTC CIPN 20 data in patients receiving chemotherapy not known to cause CIPN.

Results

Cisplatin-induced neuropathy was more similar to neuropathy in patients receiving oxaliplatin than in those receiving paclitaxel. The cisplatin and oxaliplatin groups exhibited the coasting phenomenon and more prominent upper extremity symptoms than lower extremity symptoms during chemotherapy administration weeks. In contrast, paclitaxel-treated patients did not, on average, exhibit the coasting phenomenon; additionally, lower extremity symptoms were more prominent during the weeks when paclitaxel was administered. Cisplatin-induced neuropathy was less severe than was seen in patients in the other two groups, potentially because the cisplatin-receiving patients were younger. Patients receiving AC did not report substantial EORTC CIPN 20 changes.

Conclusion

Understanding neuropathy similarities and differences with various chemotherapy agents may help elucidate CIPN processes and facilitate means to prevent and/or treat established CIPN.

Trial registration

NCT02677727

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Change history

References

  1. Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32:1941–1967

    Article  CAS  Google Scholar 

  2. Loprinzi CL, Maddocks-Christianson K, Wolf SL, Rao RD, Dyck PJB, Mantyh P, Dyck PJ (2007) The paclitaxel acute pain syndrome: sensitization of nociceptors as the putative mechanism. Cancer J 13:399–403

    Article  Google Scholar 

  3. Loprinzi CL, Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A, le-Lindqwister NA, Soori GS, Jaslowski AJ, Novotny PJ, Lachance DH (2011) Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol 29:1472–1478

    Article  CAS  Google Scholar 

  4. Pachman DR, Qin R, Seisler D et al (2014) Clinical course of patients with oxaliplin-associated neuropathy: N08CB (Alliance). J Clin Oncol 32:3595

    Article  Google Scholar 

  5. Wolf SL, Barton DL, Qin R, Wos EJ, Sloan JA, Liu H, Aaronson NK, Satele DV, Mattar BI, Green NB, Loprinzi CL (2012) The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. Support Care Cancer 20:625–632

    Article  Google Scholar 

  6. Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A, le-Lindqwister NA, Soori GS, Jaslowski AJ, Kelaghan J, Novotny PJ, Lachance DH, Loprinzi CL (2012) Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1. Cancer 118:5171–5178

    Article  Google Scholar 

  7. Pachman DR, Qin R, Seisler D, Smith EML, Kaggal S, Novotny P, Ruddy KJ, Lafky JM, Ta LE, Beutler AS, Wagner-Johnston ND, Staff NP, Grothey A, Dougherty PM, Cavaletti G, Loprinzi CL (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059–5068

    Article  Google Scholar 

  8. Lavoie Smith EM, Barton DL, Qin R, Steen PD, Aaronson NK, Loprinzi CL (2013) Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 questionnaire. Qual Life Res 22:2787–2799

    Article  Google Scholar 

  9. Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, Hoang-Xuan K, Lantéri-Minet M, Grant R, Huddart R, Moynihan C, Maher J, Lucey R (2005) The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 41:1135–1139

    Article  CAS  Google Scholar 

  10. Gewandter JS, Brell J, Cavaletti G, Dougherty PM, Evans S, Howie L, McDermott MP, O’Mara A, Smith AG, Dastros-Pitei D, Gauthier LR, Haroutounian S, Jarpe M, Katz NP, Loprinzi C, Richardson P, Lavoie-Smith EM, Wen PY, Turk DC, Dworkin RH, Freeman R (2018) Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations. Neurology 91:403–413

    Article  Google Scholar 

  11. Grunberg SM, Sonka S, Stevenson LL, Muggia FM (1989) Progressive paresthesias after cessation of therapy with very high-dose cisplatin. Cancer Chemother Pharmacol 25:62–64

    Article  CAS  Google Scholar 

  12. LoMonaco M, Milone M, Batocchi AP, Padua L, Restuccia D, Tonali P (1992) Cisplatin neuropathy: clinical course and neurophysiological findings. J Neurol 239:199–204

    Article  CAS  Google Scholar 

  13. Podratz JL, Knight AM, Ta LE, Staff NP, Gass JM, Genelin K, Schlattau A, Lathroum L, Windebank AJ (2011) Cisplatin induced mitochondrial DNA damage in dorsal root ganglion neurons. Neurobiol Dis 41:661–668

    Article  CAS  Google Scholar 

  14. Quasthoff S, Hartung HP (2002) Chemotherapy-induced peripheral neuropathy. J Neurol 249:9–17

    Article  CAS  Google Scholar 

  15. Choi J, Kong K, Mozaffar T, Holcombe RF (2006) Delayed oxaliplatin-associated neurotoxicity following adjuvant chemotherapy for stage III colon cancer. Anti-Cancer Drugs 17:103–105

    Article  CAS  Google Scholar 

  16. Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK (2004) Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 29:387–392

    Article  CAS  Google Scholar 

  17. Kidwell KM, Yothers G, Ganz PA, Land SR, Ko CY, Cecchini RS, Kopec JA, Wolmark N (2012) Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01. Cancer 118:5614–5622

    Article  CAS  Google Scholar 

  18. Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV (2013) Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol 31:2699–2707

    Article  Google Scholar 

  19. Land SR, Kopec JA, Cecchini RS, Ganz PA, Wieand HS, Colangelo LH, Murphy K, Kuebler JP, Seay TE, Needles BM, Bearden JD III, Colman LK, Lanier KS, Pajon ER Jr, Cella D, Smith RE, O’Connell MJ, Costantino JP, Wolmark N (2007) Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 25:2205–2211

    Article  CAS  Google Scholar 

  20. Tofthagen C, McAllister RD, McMillan SC (2011) Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin. Clin J Oncol Nurs 15:182–188

    Article  Google Scholar 

  21. Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L, Flynn KA, Atherton P, Seisler D, Qamar R, Lewis GC, Grothey A (2014) Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol 32:997–1005

    Article  CAS  Google Scholar 

Download references

Funding

Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under the Award Number UG1CA189823 (Alliance for Clinical Trials in Oncology NCORP Grant), UG1CA233160, UG1CA233196, UG1CA233339, and UG1CA232760; https://acknowledgments.alliancefound.org.

Author information

Authors and Affiliations

  1. Indiana University Simon Cancer Center, Indianapolis, IN, USA

    Costantine Albany & Lawrence Einhorn

  2. Alliance Statistics and Data Center, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA

    Travis Dockter, Eric Wolfe, Jennifer Le-Rademacher & Jacqueline M. Lafky

  3. Johns Hopkins, Baltimore, MD, USA

    Nina Wagner-Johnston

  4. University of Michigan, Ann Arbor, MI, USA

    Ellen Smith

  5. Mayo Clinic, Rochester, MN, USA

    Deirdre Pachman, Nathan Staff, Charles L. Loprinzi & Brian A. Costello

  6. Washington University, St Louis, MO, USA

    Cynthia Ma

Authors
  1. Costantine Albany
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Travis Dockter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eric Wolfe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jennifer Le-Rademacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nina Wagner-Johnston
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lawrence Einhorn
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jacqueline M. Lafky
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ellen Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Deirdre Pachman
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Nathan Staff
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Cynthia Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Charles L. Loprinzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Brian A. Costello
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Charles L. Loprinzi.

Ethics declarations

Conflict of interest

Dr. Einhorn owns Amgen and Biogenidec stock; Dr. Loprinzi reports personal fees from PledPharma, personal fees from Disarm Therapeutics, personal fees from Asahi Kasei, personal fees from Metys Pharmaceuticals, personal fees from OnQuality, personal fees from NKMax, and personal fees from Mitsubishi Tanabe, outside the submitted work; Dr. Wagner-Johnston reports personal fees from Regeneron, ADC Therapeutics, CALIB-R, Verastem, outside the submitted work; None of the other authors noted any potential conflicts of interest.

Disclaimer

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Highlights

The manuscript provides new insights into the natural history of cisplatin-induced neuropathy via the use of the EORTC CIPN 20 instrument. Through comparing and contrasting to other neurotoxic and non-neurotoxic chemotherapy agents, including oxaliplatin, paclitaxel, and doxorubicin/cyclophosphamide, unique differences in chemotherapy-induced peripheral neuropathy (CIPN) are better understood. Such information should facilitate the evaluation of neuropathy for clinical trials and may help elucidate better means for neuropathy prevention.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Albany, C., Dockter, T., Wolfe, E. et al. Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724). Support Care Cancer 29, 833–840 (2021). https://doi.org/10.1007/s00520-020-05543-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-020-05543-5

Keywords

Search

Navigation